Phaseline

Targets › NADS

NADS: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Sep 2027.

Open in Phaseline: the race on NADS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Douglas SealsNicotinamide riboside
NAD+ precursor that reverses age-related arterial dysfunction
NADSPhase 2HypertensionSep 2027

Conditions

Hypertension (1)

Modalities

small molecule (1)

Companies

Douglas Seals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.